Condition: Hypertension · Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.
This description comes directly from the study's public registry record.
Jia Song · China 86+18503817651 · songjia@vybio.com
Xiaoqi Cao · China 86+15238088632 · caoxiaoqi@vybio.com
Always discuss trial participation with your own doctor first.
| Hangzhou First People's Hospital | Hangzhou, China | Recruiting |
| Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine | Shanghai, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07254481